Uitgave bijlage 1/2021
Guidelines on COVID-19 and heart disease
Inhoudsopgave (5 Artikelen)
Open Access
Introduction
Four guidelines on cardiovascular complications and cardiovascular disease, prognosis and treatment in COVID‑19
H. J. Siebelink, C. W. Jansen, E. Belfroid, J. Hoogervorst-Schilp
Open Access
Guideline
How often and to what extent do admitted COVID-19 patients have signs of cardiac injury?
M. A. W. Habets, H. N. Sturkenboom, R. A. Tio, E. Belfroid, J. Hoogervorst-Schilp, H. J. Siebelink, C. W. Jansen, P. C. Smits
Open Access
Guideline
Impact of cardiovascular disease and cardiovascular risk factors in hospitalised COVID-19 patients
L. S. D. Jewbali, J. Hoogervorst-Schilp, E. Belfroid, C. W. Jansen, F. W. Asselbergs, H. J. Siebelink
Open Access
Guideline
The effects of ACE2 expression mediating pharmacotherapy in COVID-19 patients
R. R. J. van Kimmenade, E. Belfroid, J. Hoogervorst-Schilp, H. J. Siebelink, C. W. Janssen, Y. Pinto
Open Access
Guideline
Effect of anticoagulant therapy in COVID-19 patients
R. G. Tieleman, F. A. Klok, E. Belfroid, J. Hoogervorst-Schilp, I. Schalkers, C. W. Jansen, H. J. Siebelink